Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients:The imperative for safety assessment studies  

作　　者：Mina Tharwat Ahmed Tawheed Mohamed El-Kassas 

机构地区：[1]Department of Tropical Medicine and Gastroenterology,Faculty of Medicine,Aswan University,Aswan 81528,Egypt [2]Department of Endemic Medicine,Faculty of Medicine,Helwan University,Cairo 11795,Egypt

出　　处：《World Journal of Clinical Cases》2025年第9期56-59,共4页世界临床病例杂志（英文）

摘　　要：Hepatocellular carcinoma(HCC)is the most prevalent cancer of the hepatobiliary tract and the third leading cause of cancer-related mortality worldwide.Atezolizumab and bevacizumab combination is currently considered among the frontline treatment modalities for advanced unresectable HCC.Most studies examining this combination were focused on evaluating its effectiveness.Despite numerous case reports documenting some side effects,there is a limited number of large-scale studies assessing these side effects.In this article,we comment on the case report by Park et al published recently,reporting a fatal intra-tumoral hemorrhage in a patient with HCC who received systemic therapy in the form of the combination of atezolizumab and bevacizumab.

关 键 词：Hepatocellular carcinoma Atezolizumab BEVACIZUMAB HEMORRHAGE Side effects 

分 类 号：R735.7[医药卫生—肿瘤]